GO
Loading...

Life Sciences

More

  • AP IMPACT: 'Vaccine court' keeps claimants waiting Monday, 17 Nov 2014 | 1:24 PM ET

    WASHINGTON— All but broken by her son's violent and unexplained seizures, by so many panicked trips from the crib to the emergency room, Jeffrey McCord's mom thought her desperate search for both answers and help was finally over. A system intended to speed help to vaccine-injured Americans has instead heaped additional suffering on thousands of families, The...

  • UPDATE 1-Juno Therapeutics files for IPO Monday, 17 Nov 2014 | 7:23 AM ET

    Nov 17- Juno Therapeutics Inc, a biopharmaceutical company that is working on cancer treatments, filed with U.S. regulators for an initial public offering of common stock. Seattle- based Juno, which has raised more than $310 million in funding since April this year, counts venture capital firm ARCH Venture Fund VII LP as one of its major investors, with a stake of...

  • Juno Therapeutics files for IPO Monday, 17 Nov 2014 | 6:32 AM ET

    Nov 17- Juno Therapeutics Inc filed with U.S. regulators for an initial public offering of its common stock. Morgan Stanley, J.P. Morgan and Goldman Sachs& Co were underwriting the IPO, the biopharmaceutical company told the U. S Securities and Exchange Commission in a preliminary prospectus on Monday. The filing included a nominal fundraising target of about...

  • DAKAR/ BRUSSELS, Nov 14- Medecins Sans Frontiers "wasted time" by waiting too long to call for vaccines to fight an unprecedented outbreak of Ebola in West Africa, a veteran of the medical charity told Reuters. The group's response to the epidemic which has so far killed more than 5,000 people has been widely praised by governments and the World Health Organization.

  • Nov 10- Cancer vaccine maker Dendreon Corp filed for Chapter 11 bankruptcy protection on Monday after its potential blockbuster cancer drug failed to live up to expectations, saddling the company with heavy debt. Dendreon's stock was down nearly 62 percent at 36 cents in premarket trading. Under the agreements, senior noteholders will support a plan of...

  • NEW YORK, Nov 9- Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros in Ebola research, with the lion's share going to the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and the...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros into Ebola research, with the lion's share going to fast-track the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and...

  • TOKYO, Oct 30- Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company...

  • UPDATE 1-Pfizer meningitis vaccine wins U.S. approval Wednesday, 29 Oct 2014 | 3:06 PM ET

    Oct 29- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday. It is the first approved U.S. vaccine that prevents invasive disease caused by the bacterium Neisseria meningitidis B, a...

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate production and clinical testing of three...

  • *European Commission to provide 100 million euros. The move shows how momentum is building to get medical interventions-- and particularly vaccines-- to West Africa as soon as possible to control the world's worst Ebola outbreak, which, according to official figures, has killed nearly 5,000 people, most of them in Liberia, Sierra Leone and Guinea.

  • GSK sees first Ebola vaccine doses ready late this year Wednesday, 22 Oct 2014 | 8:08 AM ET

    LONDON, Oct 22- GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production. "I fully anticipate that the initial supply should be available before the year end," Chief Executive Andrew Witty told reporters on Wednesday after reporting...

  • *J&J says has discussed collaboration with GlaxoSmithKline. Johnson& Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine. The World Health Organization hopes that tens of thousands of people in...

  • J&J, GSK ready to collaborate on Ebola vaccine work Wednesday, 22 Oct 2014 | 6:11 AM ET

    LONDON, Oct 22- Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson& Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration. J&J, which aims to have at least 1 million doses of its two-step vaccine available next year, said on Wednesday that vaccine makers would...

  • LONDON, Oct 22- Johnson& Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May. There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two- from...

  • Oct 22- Johnson& Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...